ATAI Earnings — AtaiBeckley Inc. Common Stock Post-ER Performance | BigEarnings
ATAI — AtaiBeckley Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$4.34
Market Cap$1.6B
P/E—
52W Range$2.00 – $6.75
Next Earnings2026-08-06
About AtaiBeckley Inc. Common Stock
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
